Adaptin Bio (APTN) Total Current Liabilities (2022 - 2026)

Adaptin Bio has disclosed Total Current Liabilities across 5 years of filings, most recently posting $2.5 million for Q1 2026.

• Quarterly Total Current Liabilities rose 123.83% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 123.83% YoY) and the FY2025 annual result came in at $2.1 million, down 51.41% from the prior year.
• Total Current Liabilities rose to $2.5 million in Q1 2026, from $2.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $4.3 million in Q4 2024 and bottomed at $27804.0 in Q4 2022.
• The 5-year median for Total Current Liabilities is $672190.0 (2024), against an average of $1.2 million.
• Year-over-year, Total Current Liabilities soared 3730.9% in 2024 and plunged 51.41% in 2025.
• Adaptin Bio's Total Current Liabilities stood at $27804.0 in 2022, then surged by 307.41% to $113277.0 in 2023, then soared by 3730.9% to $4.3 million in 2024, then plunged by 51.41% to $2.1 million in 2025, then climbed by 17.7% to $2.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $2.5 million, $2.1 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.